Anthony Levy
French Institute of Health and Medical Research
11 Papers
21 Citations
Anthony Levy is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Medicine & Carfilzomib. The author has an hindex of 4, co-authored 10 publications.
Chat about Author
Papers
Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020.
Arthur Bobin,Evelyne Liuu,Niels Moya,Cécile Gruchet,Florence Sabirou,Anthony Levy,Helene Gardeney,Laly Nsiala,Laura Cailly,Stéphanie Guidez,Cécile Tomowiak,Thomas Systchenko,Vincent Javaugue,Geraldine Durand,Xavier Leleu,Mathieu Puyade +15 more
TL;DR: The most recent advances in MM therapeutics, which have undergone major transformations over the past decade, are enumerated and comment on.
27
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
Guillemette Fouquet,Stéphanie Guidez,Valentine Richez,Anne-Marie Stoppa,Christophe Le Tourneau,Margaret Macro,Cécile Gruchet,Arthur Bobin,Niels Moya,Thomas Syshenko,Florence Sabirou,Anthony Levy,Paul Franques,Helene Gardeney,Lionel Karlin,Lotfi Benboubker,M. Ouali,Jean-Claude Vedovato,Pierre Ferré,Mariya Pavlyuk,Michel Attal,Thierry Facon,Xavier Leleu +22 more
TL;DR: This study suggests that egression of tumor cells to the blood stream can represent a novel therapeutic strategy for MM, however, because of significant hematological toxicity, this study had to be discontinued.
Carfilzomib weekly 20/56 mg/m2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.
Valentine Richez,Cécile Gruchet,Stéphanie Guidez,Guillemette Fouquet,Isabelle Azais,Geraldine Durand,Vincent Javaugue,Antoine Brigaud,Florent Plasse,Jeremie Diolez,Antoine Machet,Niels Moya,Helene Gardeney,Paul Franques,Arthur Bobin,Anthony Levy,Florence Sabirou,Anthony Bonnin,Celine Dieval,Sylvain Primault,Jocelyn Barrier,Emmanuel Fleck,Sabrina Bouyier,Claire Daras,Isabelle Princet,Delphine Bauwens,Laurence Legros,Jean-Gabriel Fuzibet,Angela Gil,Frank Bridoux,Hervé Avet-Loiseau,Xavier Leleu +31 more
TL;DR: Results indicated that improved patient-reported outcomes, especially increased adherence, are significant mediators of the association between treatment with deferasirox DT vs FCT, and the reduction from baseline in serum ferritin achieved over 6 months of treatment.
8
Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
Arthur Bobin,Cécile Gruchet,Stéphanie Guidez,Helene Gardeney,Laly Nsiala Makunza,Mathilde Vonfeld,Anthony Levy,Laura Cailly,Florence Sabirou,Thomas Systchenko,Niels Moya,Xavier Leleu +11 more
TL;DR: In this article, a peptide-conjugated alkylator with a completely new mechanism of action, melflufen, was proposed to address the lack of options for patients with relapsed or refractory multiple myeloma.
7
Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients.
Helene Gardeney,Arthur Bobin,Cécile Gruchet,Florence Sabirou,Anthony Levy,Laly Nsiala,Laura Cailly,Cécile Tomowiak,Jose Torregrosa,Niels Moya,Cyrille Hulin,Xavier Leleu,Stéphanie Guidez +12 more
TL;DR: It is possible that immunomonitoring, minimal residual disease (MRD), and genomic risk-adaptation will become key elements of the treatment decisions on triplet-based regimens on multiple myeloma patients.
5